Navigation Links
King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion
Date:11/24/2008

ts, together with other new medicines expected to emerge from the pipeline, will further advance King's ability to deliver outstanding stockholder value.

King expects the transaction will be accretive to its diluted earnings per share, excluding any special items, in the second full year following completion of the transaction and anticipates achieving synergies of $50 million to $70 million over the same time period. King expects that these synergies will be derived principally from G&A, R&D, and savings to be achieved by avoiding the expense of hiring additional sales representatives for the anticipated launch of REMOXY(R).

King currently anticipates that the transaction will be completed by the end of 2008. However, King's amended offer is subject to the satisfaction of customary conditions contained in the merger agreement, which also will be described in the amended tender offer documents to be filed with the SEC and mailed to Alpharma stockholders.

Credit Suisse and Wachovia Securities are acting as financial advisors, and Dewey & LeBoeuf LLP is acting as legal counsel, to King. Banc of America Securities LLC and Simpson Thacher & Bartlett LLP are acting as financial advisor and legal counsel for Alpharma, respectively.

About REMOXY

REMOXY, an investigational drug, is a unique, abuse-resistant, controlled-release oxycodone for moderate-to-severe chronic pain. REMOXY's high viscosity, liquid formulation in a hard gelatin capsule is designed to resist common methods of prescription drug misuse and abuse. The New Drug Application for REMOXY is currently undergoing a priority review by the Food and Drug Administration ("FDA"). If approved, the companies believe REMOXY could be the first oxycodone on the market that is designed to reduce the risk of misuse and abuse. REMOXY is a proposed brand name that is subject to FDA approval.


'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the Presidents Council on Physical Fitness and Sports, to Board of Directors
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
4. Keryx Biopharmaceuticals Receives Nasdaq Notification
5. Purdue Pharma L.P. Announces a Global Strategic Alliance With Infinity Pharmaceuticals to Advance Discovery and Development Programs in Oncology and Neuropathic Pain
6. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
7. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
8. MiddleBrook Pharmaceuticals Reports Third Quarter 2008 Financial Results
9. MAP Pharmaceuticals Reports Third Quarter of 2008 Financial Results
10. Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit
11. Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... (HealthDay News) -- A comparison of two of the ... laparoscopic gastric bypass helped patients shed more excess pounds ... of short-term complications and long-term hospitalizations. Gastric-bypass surgery ... so your body does not absorb all the calories ... of Health. Gastric banding is a type of weight-loss ...
(Date:10/31/2014)... By Steven Reinberg HealthDay ... skin condition eczema may increase slightly the risk of broken bones ... of 34,500 adults, researchers found that among 7 percent of people ... had a bone or joint injury and 0.6 percent had an ... people without eczema, those with the skin condition had more than ...
(Date:10/30/2014)... for injuries and damage to the joints, including articular ... a hard material that caps the ends of bones ... engineers, exploring ways to toughen up engineered cartilage and ... developments this week in the journal Proceedings of ... with engineered tissue is that the mechanical properties are ...
(Date:10/30/2014)... by NIH grantees predicts that women must take the ... vaginal sex, whereas just two doses per week can ... finding helps explain why two large clinical trials testing ... show efficacy. Participants in the VOICE and ... antiretroviral) for HIV prevention were counseled to take one ...
(Date:10/30/2014)... Don Allred Insurance, a leading provider ... for North Carolina residents, is excited to announce the ... Hill Mall. The new branch has been up and ... through all facets of the insurance selection process from ... Scott Allred couldn’t be happier with the timing of ...
Breaking Medicine News(10 mins):Health News:Study Compares 2 Common Weight-Loss Surgeries 2Health News:Study Compares 2 Common Weight-Loss Surgeries 3Health News:Eczema Tied to Bone Fracture Risk in Study 2Health News:Making lab-grown tissues stronger 2Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Allred Insurance Satellite Office Grand Opening 2
... Proactive, Reducing Risks for Dementia NEW YORK, May 6 Look ... a brisk walk, eaten dark leafy vegetables or toured a museum ... of lifestyle choices that can pay off now and in the ... interactive Web site - www.alzprevention.org ...
... Auction Raises Funds for Earth Day Network PHOENIX, ... Pop-surrealist artist Jeff Sadowski has won the PurexSavesGreen tote ... and Green Purex-hilaration" slogan and funky leaf design took ... by creative consumers from all 50 states. Mr. Sadowski ...
... in ICU and Writes Notes to Fiancée , ... Tucson, Ariz. (Vocus) ... Center (UMC) after making medical history. He is only the third person ... transplant on the same day after living with the SynCardia temporary ...
... data may help identify difficult to diagnose disease states ... Corporation (Nasdaq: SMTS ) announced today that ... presentations at the Pediatric Academic Societies (PAS) annual conference ... studies focused on early applications of the technology in ...
... an industry with low morale, high employee turnover and ... reputation with both consumers and workers for decades. It ... one call center has discarded all this historical baggage ... work in America while repeatedly shattering the benchmark for ...
... of current legislation, guidance on qualification for funds and a demonstration ... ... Mt. Arlington, New Jersey (PRWEB) May 6, 2009 -- ... of IT services to specialty medical practices in New Jersey and ...
Cached Medicine News:Health News:Alzheimer's Foundation of America Lays Out Strategies for Healthy Aging 2Health News:Alzheimer's Foundation of America Lays Out Strategies for Healthy Aging 3Health News:Photo: Wisconsin Artist Wins Purex Saves Green Tote Bag Design Contest 2Health News:Photo: Wisconsin Artist Wins Purex Saves Green Tote Bag Design Contest 3Health News:Photo: Wisconsin Artist Wins Purex Saves Green Tote Bag Design Contest 4Health News:Total Artificial Heart Patient 3rd in the World to Receive Dual Transplants 2Health News:25 Clinical Abstracts at National Conference Spotlight Clinical Utility of Somanetics INVOS System in Neonates 2Health News:25 Clinical Abstracts at National Conference Spotlight Clinical Utility of Somanetics INVOS System in Neonates 3Health News:25 Clinical Abstracts at National Conference Spotlight Clinical Utility of Somanetics INVOS System in Neonates 4Health News:The Beryl Companies Reinvents Call Center, Shatters Old Paradigm 2Health News:The Beryl Companies Reinvents Call Center, Shatters Old Paradigm 3Health News:New Jersey IT Services Firm to Host Educational Luncheon Event, EMR & Information Technology for the Specialty Medical Practice 2Health News:New Jersey IT Services Firm to Host Educational Luncheon Event, EMR & Information Technology for the Specialty Medical Practice 3
(Date:10/31/2014)... -- Encision Inc. (OTCQB:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of $2.279 ... or $(0.04) per share. These results compare to net ... $50 thousand, or $(0.01) per share, in the year-ago ...
(Date:10/31/2014)... October 30, 2014 ... the addition of the  "Process Validation in the ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key ... Risk Based Approach to Process Validation for Pharmaceutical ... FDA Process Validation Guidance ...
(Date:10/31/2014)... 2014  AbbVie (NYSE: ABBV ) ... ended Sept. 30, 2014. "Our ... business with double-digit growth from HUMIRA and several ... 14 percent in the quarter excluding lipids," said ... AbbVie.  "We exceeded our outlook for the quarter ...
Breaking Medicine Technology:Encision Reports Second Quarter Fiscal Year 2015 Results 2Encision Reports Second Quarter Fiscal Year 2015 Results 3Encision Reports Second Quarter Fiscal Year 2015 Results 4Encision Reports Second Quarter Fiscal Year 2015 Results 5Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24
... Reportlinker.com announces that a new market research report ... Global Orthopedic Prosthetics Industry ... the worldwide markets for Orthopedic Prosthetics in US$ ... Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis, ...
... announces that a new market research report is ... Fluoroscopy And Mobile C-Arms Industry ... the worldwide markets for Fluoroscopy And Mobile C-Arms ... segments: Fluoroscopy, and Mobile C-Arms (Full Size C-Arms, ...
Cached Medicine Technology:Reportlinker Adds Global Orthopedic Prosthetics Industry 2Reportlinker Adds Global Fluoroscopy And Mobile C-Arms Industry 2
... monomeric contrast medium for intravascular and body ... a decade of clinical experience and use ... proven to be a valuable part of ... departments.Results from large multicentre monitoring trials1-3 confirm ...
... MultiHance (gadobenate dimeglumine) is a paramagnetic ... is complexed with gadobenate, a chelating agent ... around the godolinium ion. It is salified ... is endowed with all the physico-chemical features ...
... U.S. in 1993 to provide contrast enhancement ... detect lesions of the brain, spinal cord, ... approval for adult body and high-dose CNS ... OMNISCAN comes in different sizes to accommodate ...
... When MAGNEVIST (gadopentetate dimeglumine) injection was ... revolutionary concept of contrast-enhanced magnetic resonance imaging ... agent for use in MRI. Today, the ... indications in CNS, head, neck and body. ...
Medicine Products: